A Universal Mechanism of Action
Recce’s New Class of Synthetic Anti-Infectives have a universal mechanism of action that has the potential to overcome cellular mutation in bacteria and viruses.
Recce Pharmaceuticals have developed two primary drug candidates:
RECCE 327 (bacterial infections) and;
RECCE 529 (viral infections).
Recce Pharmaceuticals continues to strengthen and expand their product pipeline in order to find a treatment for ‘difficult to treat’ bacterial and viral infections - including their mutated forms.
Image for illustrative purposes only